Abbott completes AMO acquisition

Article

Abbott Laboratories has completed its acquisition of Advanced Medical Optics (AMO), paying $1.24 billion for 83% of the fully-diluted stock and assuming around $1.4 billion of AMO's long-term debt.

Abbott Laboratories has completed its acquisition of Advanced Medical Optics (AMO), paying $1.24 billion for 83% of the fully-diluted stock and assuming around $1.4 billion of AMO's long-term debt.

Scott Stoffel, director of financial and litigation communications at Abbott remarked, "Our four major business divisions all delivered double-digit percentages of growth during the past year, resulting in 14% growth of our full-year 2008 sales. This leaves us in a very confident position for purchasing AMO, which is a global leader in eye-care devices."

As a subsidiary of Abbott, AMO will now be known as Abbott Medical Optics. The sales representatives, customer service team and pricing and ordering structure will remain the same.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.